Skip to main content
HR 6930 116th Congress House Health Administrative law and regulatory procedures Advanced technology and technological innovations Buy American requirements Department of Health and Human Services Drug safety, medical device, and laboratory regulation Foreign and international corporations Government information and archives Government studies and investigations Health technology, devices, supplies Income tax credits Income tax deductions Manufacturing Prescription drugs Taxation of foreign income Technology assessment Wages and earnings

MADE in America Act of 2020

Introduced: May 19, 2020 Introduced by: Carter, Earl L. "Buddy" Republican · Georgia See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 19, 2020
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 19, 2020
Introduced in House
 Plain-English summary Congressional Research Service

Manufacturing API, Drugs, and Excipients in America Act of 2020 or the MADE in America Act of 2020

This bill establishes a tax credit for taxpayers engaged in medical production activities in certain areas and contains other provisions related to pharmaceuticals.

An eligible taxpayer may claim a tax credit equal to 30% of qualified expenditures related to the production of pharmaceuticals, medical devices, or other related items in a designated qualified opportunity zone with a poverty rate higher than 30%.

In addition, the Food and Drug Administration shall continue a program to evaluate new drug manufacturing technologies included in an application for approval of a drug or biological product. The bill imposes various requirements on this program, including deadlines for evaluating such a technology.

Furthermore, the Department of Health and Human Services shall establish or expand programs to promote regulatory consistency and cooperation with drug regulatory authorities in other countries.

What's happening now May 19, 2020

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

 Committees of jurisdiction 2
 Cosponsors 5
All 5 Democratic 1 Republican 4